EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis - FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with commen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results